Reuters logo
BRIEF-Cyclopharm expects FY16 underlying EBITDA of about $3.4 mln
February 5, 2017 / 11:59 PM / 8 months ago

BRIEF-Cyclopharm expects FY16 underlying EBITDA of about $3.4 mln

Feb 6 (Reuters) - Cyclopharm Ltd

* Confirms it remains on track to record initial sales of ultralutetm in first half of 2017

* Expects to report record sales revenue for 2016 full year of $14.4 million and underlying EBITDA of approximately $3.4 million Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below